Trigeminal stimulation
A superhighway to the brain?
Seizures are characterized by hypersynchronous neuronal discharges, and desynchronizing stimuli abort and sometimes prevent seizures. The most direct but invasive method has been the application of electrical cortical stimulation at seizure onset. This successful termination of seizures has formed the basis for translational research involving implantable seizure detection and neurostimulation devices. The pioneering work of Moruzzi and Magoun in 1949 1 demonstrated that stimulation of the ascending reticular activating system (ARAS) can have a desynchronizing effect on cortical rhythms. This system not only projects widely throughout cortex, but also receives collateral input from all sensory systems.
These observations eventually led to the notion of treating seizures by providing additional sensory input. Some patients assert they can abort seizures by pinching themselves, or by thinking certain thoughts; one study suggested that auditory stimuli can stop absence seizures 2 while another reported that "trigeminal stimulation," supraorbital pressure by a physician, attenuated grand mal seizures. 3 To affect cortex widely, stimulation should be diffuse and nonsomatotopic: of the cranial nerves, the ones best fulfilling this requirement are V, IX, and X. The first widespread practical application of this concept was vagus nerve stimulation (VNS). VNS may have its effect through bilateral activation of the ARAS, but also through multiple pathways traversing subcortical structures, including the locus ceruleus (via augmented noradrenergic action) and the nucleus tractus solitarius. 4 VNS, available in the United States since 1998, has become a standard treatment for intractable seizures, though reported reductions in seizure frequency vary widely and few patients become seizure-free. 5 In this issue of Neurology ® , DeGiorgio et al. 6 report the results of stimulation of the trigeminal nerve in its periorbital cutaneous nerve distribution on the forehead for 50 patients with drug-resistant epilepsy. Active stimulation was performed via a single large gel electrode placed across both sides of the forehead. There were reductions from baseline frequency of complex partial and generalized tonic-clonic seizures. 6 Furthermore, mood improved as assessed by the Beck Depression Inventory. The treatment group consisted of 25 patients randomized to receive 120 Hz stimulation (30 seconds on after 30 seconds off) over a minimum period of 12 hours. An active control group of 25 received 2 Hz stimulation for 2 seconds followed by 90 seconds without stimulation, with a lower pulse duration (50 ms vs 100 ms). (Evidence from VNS studies indicated that stimulation frequencies faster than 20 Hz depolarizes A and B fibers, but avoids activation of unmyelinated C fibers mediating pain 5 ; it remains unclear which fiber types mediate the antiseizure effect.
)
The treatment period lasted 18 weeks, after a 6-week baseline. There were 3 primary outcomes: median % change in seizure frequency from baseline, response ratio, and responder rate (% of patients with 50% or more reduction in seizure frequency). Only one of these outcomes was significant: the responder rate of the treatment group declined by 17.8% at 6 weeks and 40.5% at 18 weeks. Median percent reduction of the monthly seizure frequency over the entire 18-week period was disappointing: 216.1% for the treatment group, 28.0% for the control group (p 5 NS). Limitations include the small sample size and a possibly important difference in baseline seizure frequency between groups (treatment 8.7/month, control 4.8/month); therefore, while this study provides Class II evidence that trigeminal nerve stimulation (TNS) may be effective, a robust effect was not apparent.
The appeal of TNS is that, unlike VNS, it is a nonsurgical technique. The bilateral stimulation could be advantageous because the central connections of the Vth nerve are both crossed and uncrossed, with rich connections to subcortical structures, including the locus ceruleus, and to cortex via the ARAS and projections from other subcortical nuclei. The forehead stimuli were well-tolerated with the exception of headache and skin irritation, though better descriptions of patient experiences are needed. Some patients may find adherence to use of the device for 12 hours per day onerous. Application only during sleep would be a pragmatic and desirable goal of TNS.
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The best route and anatomical site for therapeutic electrical stimulation of the brain for epilepsy remains an intriguing question. Exploratory work in animals has also suggested that seizures might be affected by stimulation of a portion of the IXth nerve. 7 The results of the current study of Vth nerve stimulation cannot be compared directly either to those experiments or to the large data involving the Xth nerve. Would concurrent neurostimulation of more than one site be advantageous and enhance the effect, or would it somehow be antagonistic? Will invasive forms of neurostimulation provide greater benefit? Many questions need answers.
Although we do not know the best electrical pathway to the brain for seizure control, the trigeminal nerve, as the largest cranial nerve, is a sort of superhighway. It has broad connections bilaterally, can be stimulated easily, and so is a contender. The beneficial effect demonstrated by DeGiorgio et al. was modest but is sufficient to encourage design of a more definitive study.
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